MAPT and Alzheimer disease: These studies revealed that proportionally higher levels of CREB3L2 were present in ATF4 coimmunoprecipitates from AD brains than those found in controls (131% average enrichment, P = 0.013; Fig. 7A), particularly in individuals with advanced tau pathology (Braak stage ≥ V; fig.